Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing

Set Alert for Manufacturing

FDA Resumes Quality Metrics Effort With Feedback And Site Visit Initiatives

FDA’s quality metrics initiative emerges from hibernation with a two-part feedback program and a site visit program. The agency plans to collect feedback on quality metrics in certain meetings conducted during the application process – and in a pilot program. Agency staff also plan to visit firms to learn how they use quality metrics.

Manufacturing Quality United States
Advertisement

Latest From Manufacturing

Who Wants To Be 'Essential'? US FDA Considers Critical Drugs List

To address chronic shortages, FDA may create list of 'essential' drugs, but will suppliers of those products be happy to be designated 'essential'? 
Manufacturing Generic Drugs

Expert Warns Of Looming 'Capacity Crunch' For New Cell And Gene Therapy Products

Capacity shortages are looming for manufacturers wanting to develop and commercialize cell and gene therapy products over the next five years, an industry survey shows. The key finding: these firms should quickly build and staff the manufacturing facilities they will need.

Manufacturing Quality

Industry Urged To Watch And Wait For US/China Tariff War To Blow Over

Don’t do anything rash to avoid US tariffs on drug products, ingredients and supplies from China, consultants advise. It would be better to just wait to see if the tariff war blows over.

Manufacturing Trade

FDA Shortages Task Force Looks More Broadly To Tackle Root Causes

FDA’s latest drug shortages task force aims to encourage investment in the reliable manufacture of generic sterile injectables that are fundamental to the practice of medicine. While the agency’s first task force continues to work with industry to avert shortages, the second will strike at underlying structural issues that cause persistent shortages of these critical medicines.

 

United States Manufacturing

FDA's CMC Guidance For Investigational Gene Therapies Reflects Broader CMC Evolution

New draft document addresses issues with applying quality-by-design to gene therapies, accommodating the Common Technical Document format, as well as drug substance, cell bank and contract manufacturing issues. US FDA's Denise Gavin offers insights on agency thinking at gene therapy conference.

Manufacturing Regenerative Medicine

Illegal Emissions Force Sanofi Production Stoppage

Sanofi is working on technical improvements after its Mourenx site in southwest France was found to be emitting illegally high levels of solvents. Production at the site is on hold.

Manufacturing Compliance
See All
UsernamePublicRestriction

Register